This company has been marked as potentially delisted and may not be actively trading. Ritter Pharmaceuticals (RTTR) Competitors Add Compare Share Share Competitors Stock AnalysisCompetitorsTrendsBuy This Stock RTTR vs. DNTH, ABUS, AKBA, ZYBT, EOLS, XNCR, ABCL, KALV, BCYC, and ANABShould you be buying Ritter Pharmaceuticals stock or one of its competitors? The main competitors of Ritter Pharmaceuticals include Dianthus Therapeutics (DNTH), Arbutus Biopharma (ABUS), Akebia Therapeutics (AKBA), Zhengye Biotechnology (ZYBT), Evolus (EOLS), Xencor (XNCR), AbCellera Biologics (ABCL), KalVista Pharmaceuticals (KALV), Bicycle Therapeutics (BCYC), and AnaptysBio (ANAB). These companies are all part of the "medical" sector. Ritter Pharmaceuticals vs. Dianthus Therapeutics Arbutus Biopharma Akebia Therapeutics Zhengye Biotechnology Evolus Xencor AbCellera Biologics KalVista Pharmaceuticals Bicycle Therapeutics AnaptysBio Ritter Pharmaceuticals (NASDAQ:RTTR) and Dianthus Therapeutics (NASDAQ:DNTH) are both small-cap medical companies, but which is the better investment? We will contrast the two businesses based on the strength of their media sentiment, valuation, analyst recommendations, profitability, earnings, dividends, risk, institutional ownership and community ranking. Which has more risk and volatility, RTTR or DNTH? Ritter Pharmaceuticals has a beta of -0.43, indicating that its stock price is 143% less volatile than the S&P 500. Comparatively, Dianthus Therapeutics has a beta of 1.48, indicating that its stock price is 48% more volatile than the S&P 500. Do institutionals & insiders hold more shares of RTTR or DNTH? 0.8% of Ritter Pharmaceuticals shares are held by institutional investors. Comparatively, 47.5% of Dianthus Therapeutics shares are held by institutional investors. 15.4% of Ritter Pharmaceuticals shares are held by insiders. Comparatively, 8.2% of Dianthus Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a company will outperform the market over the long term. Is RTTR or DNTH more profitable? Ritter Pharmaceuticals has a net margin of 0.00% compared to Dianthus Therapeutics' net margin of -1,250.32%. Ritter Pharmaceuticals' return on equity of 0.00% beat Dianthus Therapeutics' return on equity.Company Net Margins Return on Equity Return on Assets Ritter PharmaceuticalsN/A N/A -162.05% Dianthus Therapeutics -1,250.32%-21.68%-20.88% Does the MarketBeat Community believe in RTTR or DNTH? Ritter Pharmaceuticals received 274 more outperform votes than Dianthus Therapeutics when rated by MarketBeat users. However, 96.55% of users gave Dianthus Therapeutics an outperform vote while only 70.23% of users gave Ritter Pharmaceuticals an outperform vote. CompanyUnderperformOutperformRitter PharmaceuticalsOutperform Votes30270.23% Underperform Votes12829.77% Dianthus TherapeuticsOutperform Votes2896.55% Underperform Votes13.45% Do analysts rate RTTR or DNTH? Dianthus Therapeutics has a consensus price target of $53.00, indicating a potential upside of 182.67%. Given Dianthus Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe Dianthus Therapeutics is more favorable than Ritter Pharmaceuticals.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Ritter Pharmaceuticals 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00Dianthus Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 2 Strong Buy rating(s) 3.22 Which has preferable earnings and valuation, RTTR or DNTH? Ritter Pharmaceuticals has higher earnings, but lower revenue than Dianthus Therapeutics. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioRitter PharmaceuticalsN/AN/A-$10.13MN/AN/ADianthus Therapeutics$6.52M92.43-$43.56M-$2.88-6.51 Does the media favor RTTR or DNTH? In the previous week, Dianthus Therapeutics had 17 more articles in the media than Ritter Pharmaceuticals. MarketBeat recorded 17 mentions for Dianthus Therapeutics and 0 mentions for Ritter Pharmaceuticals. Dianthus Therapeutics' average media sentiment score of 0.53 beat Ritter Pharmaceuticals' score of 0.00 indicating that Dianthus Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment Ritter Pharmaceuticals Neutral Dianthus Therapeutics Positive SummaryDianthus Therapeutics beats Ritter Pharmaceuticals on 11 of the 17 factors compared between the two stocks. Get Ritter Pharmaceuticals News Delivered to You Automatically Sign up to receive the latest news and ratings for RTTR and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart RTTR vs. The Competition Export to ExcelMetricRitter PharmaceuticalsPharmaceutical Preparations IndustryMedical SectorNASDAQ ExchangeMarket Cap$173.54M$6.53B$5.38B$8.39BDividend YieldN/A2.65%5.21%4.10%P/E Ratio-5.888.9226.8019.71Price / SalesN/A252.24389.55117.28Price / CashN/A65.8538.2534.62Price / Book37.606.466.804.50Net Income-$10.13M$143.98M$3.23B$248.18M Ritter Pharmaceuticals Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)RTTRRitter PharmaceuticalsN/A$3.76+0.5%N/A+1,168.0%$173.54MN/A-5.887DNTHDianthus Therapeutics1.282 of 5 stars$20.08+2.5%$54.33+170.6%-23.7%$645.09M$6.24M-8.0380ABUSArbutus Biopharma1.7283 of 5 stars$3.35+3.7%$5.50+64.2%-1.2%$641.46M$6.17M-7.7990News CoverageGap UpAKBAAkebia Therapeutics4.2246 of 5 stars$2.43-4.7%$6.63+172.6%+148.7%$636.14M$160.18M-10.56430High Trading VolumeZYBTZhengye BiotechnologyN/A$13.43+30.3%N/AN/A$633.44M$189.75M0.00278Gap DownEOLSEvolus3.5784 of 5 stars$9.98+1.8%$23.75+138.0%-27.1%$631.87M$266.27M-10.97170Gap UpHigh Trading VolumeXNCRXencor3.7053 of 5 stars$8.77+5.3%$29.50+236.4%-68.4%$624.00M$110.49M-2.74280ABCLAbCellera Biologics2.7406 of 5 stars$2.06+1.5%$7.50+264.1%-48.3%$614.75M$28.83M-3.38500KALVKalVista Pharmaceuticals4.3036 of 5 stars$12.18+2.4%$24.83+103.9%+2.2%$605.54MN/A-3.35100News CoveragePositive NewsBCYCBicycle Therapeutics3.7852 of 5 stars$8.60+3.1%$25.00+190.7%-62.7%$595.14M$25.72M-2.61240Gap UpANABAnaptysBio3.3078 of 5 stars$20.03+2.2%$35.88+79.1%-13.1%$588.48M$111.87M-3.29100Positive NewsGap Down Related Companies and Tools Related Companies Dianthus Therapeutics Competitors Arbutus Biopharma Competitors Akebia Therapeutics Competitors Zhengye Biotechnology Competitors Evolus Competitors Xencor Competitors AbCellera Biologics Competitors KalVista Pharmaceuticals Competitors Bicycle Therapeutics Competitors AnaptysBio Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:RTTR) was last updated on 5/22/2025 by MarketBeat.com Staff From Our PartnersJuly 2025 Rule Change to Impact Retirement InvestorsThere's a massive change from a new rule going into effect this July. And it's one the Big Banks are alread...Premier Gold Co | SponsoredA new financial chapter Porter Stansberry says what happened last week could become the defining legacy of his financial publishing ca...Porter & Company | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredWatch This Robotics Demo Before July 23rdJeff Brown, the tech legend who picked shares of Nvidia in 2016 before they jumped by more than 22,000%... ...Brownstone Research | SponsoredElon’s backup plan for AIElon knows the future isn’t about smarter AI — it’s about powering it. And this new technology is quietly b...True Market Insiders | SponsoredExclusive Offer: Target 100% Returns NowBrace yourself–this may come as a shock. It turns out that you may not have to wait decades to turn a small...ProsperityPub | SponsoredPrepare now for May 31 eventPrepare now for May 31 event Circle May 31 on your calendar This man grew up in a trailer in New Mexico. To...Stansberry Research | SponsoredMemorial Day: 59% dividend from Bitcoin (No Crypto Needed)140% Dividends from stocks like Tesla? Discover How for Just $9! For Memorial Day, get the full details of ...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Ritter Pharmaceuticals Inc Please log in to your account or sign up in order to add this asset to your watchlist. Share Ritter Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy RTTR Stock Free RTTR Stock Alerts